Prescription Transactions Revenue was GoodRx Holdings’s largest product and service line in fiscal 2025, bringing in $544.00M of $796.85M (68%).
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Prescription Transactions Revenue | $550.54M | $550.74M | $577.55M | $544.00M | ||||
| Pharma Manufacturer Solutions Revenue | $99.43M | $85.07M | $107.24M | $151.38M | ||||
| Subscription Revenue | $96.17M | $94.41M | $86.54M | $83.79M | ||||
| Other Revenue | $20.43M | $20.05M | $21.00M | $17.69M | ||||
| Total | $766.55M | $750.27M | $792.32M | $796.85M |
GoodRx Holdings brought in $796.85M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 0.6% from $792.32M in fiscal 2024. Prescription Transactions Revenue was the largest at $544.00M (68.3%), ahead of Pharma Manufacturer Solutions Revenue at $151.38M (19.0%) and Subscription Revenue at $83.79M (10.5%). The remaining line, Other Revenue, brought in $17.69M.
Compared with fiscal 2024, Pharma Manufacturer Solutions Revenue grew fastest, up 41.2% to $151.38M, while Other Revenue fell the most, down 15.8% to $17.69M. From fiscal 2022 to 2025, combined revenue from these lines grew from $766.55M to $796.85M, a compound annual growth rate of 1.3%. Prescription Transactions Revenue's share of the total fell from 71.8% to 68.3%.
GoodRx Holdings (GDRX) reports its revenue by product and service. In fiscal 2025, Prescription Transactions Revenue was its largest product and service line, bringing in $544.00M (68.3% of the total), followed by Pharma Manufacturer Solutions Revenue at $151.38M (19.0%).
Prescription Transactions Revenue was GoodRx Holdings' largest product and service line in fiscal 2025, bringing in $544.00M, or 68.3% of the $796.85M total across its four product and service lines.
Among GoodRx Holdings' product and service lines that make up at least 2% of revenue, Pharma Manufacturer Solutions Revenue grew fastest in fiscal 2025, up 41.2% from $107.24M to $151.38M.
Every figure comes from GoodRx Holdings' annual financial filings, as reported. Each line keeps the name GoodRx Holdings gives it, and years follow its fiscal calendar.
GoodRx Holdings' revenue by product and service goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.